Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novo-Nordisk A/S

58.33
+0.25000.43%
Post-market: 58.730.3968+0.68%19:59 EDT
Volume:13.42M
Turnover:778.95M
Market Cap:258.93B
PE:18.57
High:59.30
Open:58.25
Low:57.00
Close:58.08
Loading ...

Shares of Obesity Drug Makers Lower, Proposal For Medicare Coverage Dropped

Dow Jones
·
05 Apr

Is Novo Nordisk A/S (NVO) The Best Beaten Down Stock to Buy According to Analysts?

Insider Monkey
·
04 Apr

Novo Nordisk (NVO) Stock Moves -1.67%: What You Should Know

Zacks
·
04 Apr

Artisan Global Opportunities Fund Trimmed its Position in Novo Nordisk A/S (NVO)

Insider Monkey
·
03 Apr

Bernstein Sticks to Its Hold Rating for Novo Nordisk (0QIU)

TIPRANKS
·
03 Apr

Novo Nordisk Details Executive Management Changes

MT Newswires Live
·
03 Apr

Camilla Sylvest to leave Novo Nordisk after 28 years, Bloomberg reports

TIPRANKS
·
03 Apr

Novo Nordisk announces changes in Executive Management

GlobeNewswire
·
03 Apr

Novo Nordisk A/S Stock Falls Wednesday, Underperforms Market

Dow Jones
·
03 Apr

Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump

Quartz
·
02 Apr

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?

Zacks
·
02 Apr

Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales

Benzinga
·
02 Apr

Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk

Dow Jones
·
02 Apr

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Dow Jones
·
02 Apr

Novo Resources to Launch RC Drilling at Tibooburra Gold Project

TIPRANKS
·
01 Apr

Novo Nordisk A/S Stock Falls Monday, Outperforms Market

Dow Jones
·
01 Apr

Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk

Dow Jones
·
31 Mar

UBS Remains a Buy on Novo Nordisk (0QIU)

TIPRANKS
·
30 Mar

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

GlobeNewswire
·
30 Mar

Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

GlobeNewswire
·
29 Mar